Compare FSBW & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | ESPR |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 731.9M |
| IPO Year | 2011 | 2013 |
| Metric | FSBW | ESPR |
|---|---|---|
| Price | $39.38 | $2.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $46.00 | $7.60 |
| AVG Volume (30 Days) | 8.5K | ★ 5.2M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ 4.29 | N/A |
| Revenue | $4,612,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $14.94 | $2.92 |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ 44.80 | 21.31 |
| 52 Week Low | $34.61 | $0.73 |
| 52 Week High | $44.22 | $4.18 |
| Indicator | FSBW | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 41.86 |
| Support Level | $39.44 | $2.37 |
| Resistance Level | $40.67 | $3.02 |
| Average True Range (ATR) | 1.25 | 0.18 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 85.35 | 37.62 |
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.